糖尿病特殊人群降糖治疗的临床探讨
Clinical Discussion on Hypoglycemic Treatment for Special Populations with Diabetes
DOI: 10.12677/acm.2026.1641749, PDF,   
作者: 王 晟*, 屈明超:无锡市第二人民医院药学部,江苏 无锡;周 玉#:无锡卫生高等职业技术学校药学系,江苏 无锡
关键词: 糖尿病特殊人群降糖治疗临床教学个体化Diabetes Special Populations Hypoglycemic Treatment Clinical Teaching Individualization
摘要: 糖尿病作为全球范围内高发的慢性代谢性疾病,其治疗核心在于安全、有效、平稳地控制血糖,以最大限度减少并发症发生风险。在临床实践中,老年人、肝肾功能不全者、肥胖者、妊娠期女性、儿童青少年及合并心脑血管疾病等特殊糖尿病人群,由于生理及病理特点的特殊性、合并发症的复杂性以及药物代谢的差异性,降糖治疗需遵循个体化的原则,综合权衡安全性与有效性。本文基于临床教学需求,系统阐述糖尿病特殊人群的降糖治疗方案,以期为临床教学与实践提供参考,助力提升糖尿病特殊人群血糖水平管理的规范化。
Abstract: Diabetes, as a globally prevalent chronic metabolic disease, its treatment core lies in safely, effectively and steadily controlling blood sugar to minimize the risk of complications. In clinical practice, special populations such as the elderly, people with liver and kidney dysfunction, obese individuals, pregnant women, children and adolescents, and patients with concurrent cardiovascular and cerebrovascular diseases, due to their unique physiological and pathological characteristics, complex complications and differences in drug metabolism, require individualized hypoglycemic treatment, comprehensively balancing safety and efficacy. Based on the clinical teaching requirements, this article systematically expounds the hypoglycemic treatment plans for special populations with diabetes, providing references for clinical teaching and practice, and helping to improve the standardization of blood sugar level management in special populations with diabetes.
文章引用:王晟, 屈明超, 周玉. 糖尿病特殊人群降糖治疗的临床探讨[J]. 临床医学进展, 2026, 16(4): 4773-4777. https://doi.org/10.12677/acm.2026.1641749

参考文献

[1] (2023) Global, Regional, and National Burden of Diabetes from 1990 to 2021, with Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021. The Lancet (London, England), 402, 203-234.
[2] 中国2型糖尿病防治指南(2020年版) (上) [J]. 中国实用内科杂志, 2021, 41(8): 668-695.
[3] 王中瑞, 符宇, 赵瑞霞, 等. 糖尿病合并稳定型心绞痛患者发生主要不良心脑血管事件的中医预测模型构建及应用评估研究[J]. 中国全科医学, 2022, 25(20): 2450-2456.
[4] 洪天配, 母义明, 纪立农, 等. 2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识[J]. 中国糖尿病杂志, 2017, 25(6): 481-492.
[5] 王雪玲, 邓军. 甘精胰岛素联合阿卡波糖治疗糖尿病合并冠心病的疗效观察[J]. 中国实用医药, 2012, 7(20): 154-155.
[6] 章世显, 程琦, 于子翔. 冠心病合并糖尿病共病状态的研究进展[J]. 中国心血管病研究, 2025, 23(12): 1088-1093.
[7] 毕宇芳. 2型糖尿病合并慢性肾脏病患者口服降糖药治疗中国专家共识(2019年更新版)解读[J]. 内科理论与实践, 2019, 14(6): 333-336.
[8] Wilding, J.P.H. (2018) Medication Use for the Treatment of Diabetes in Obese Individuals. Diabetologia, 61, 265-272. [Google Scholar] [CrossRef] [PubMed]
[9] 张真. 司美格鲁肽联合二甲双胍治疗老年腹型肥胖2型糖尿病患者的临床效果[J]. 当代医药论丛, 2026, 24(3): 115-117.
[10] 张艳苹, 黄彬, 卢金淼, 等. 首个GIP/GLP-1双重受体激动剂: 替尔泊肽[J]. 中国临床药学杂志, 2025, 34(7): 533-539.
[11] 田慧. 老年糖尿病管理理念和策略的优化-中国老年2型糖尿病诊疗措施专家共识(2018版)解读[J]. 中华保健医学杂志, 2020, 22(1): 104-106.
[12] 苏青. α-葡萄糖苷酶抑制剂与常见药物联用的不良反应[J]. 药品评价, 2018, 15(23): 3-8+45.
[13] 简颖, 黎广荣, 徐芬. 二甲双胍所致血清维生素B12水平降低的研究现状[J]. 新医学, 2022, 53(10): 714-717.
[14] 裴舟, 罗飞宏. 中国儿童糖尿病诊治进展[J]. 诊断学理论与实践, 2024, 23(5): 461-466.
[15] American College of Obstetricians and Gynecologists (ACOG) (2019) Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstetrics & Gynecology, 133, e1-e25.